Study of Imatinib in Children With Neurofibromatosis and Airway Tumors

Neurofibroma, Plexiform Clinical Trial

Official title:

Phase 2 Study of Imatinib in Children With Neurofibromatosis and Airway Tumors

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT03688568
• Other study ID #: 1505569560
• Secondary ID: 1R01FD004830-01A
• Status: Withdrawn
• Phase: Phase 2
• Start date: September 1, 2018
• Est. completion date: September 1, 2021

Study information

• Verified date: February 2021
• Source: Indiana University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to look at a subset of plexiform neurofibromas and determine if the airway tumors are more sensitive to imatinib therapy. Funding Source - FDA OOPD

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: September 1, 2021
• Est. primary completion date: September 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Months to 12 Years

Eligibility

Inclusion Criteria:

1. Patients aged: > 6 months and < 12 years of age.

2. Diagnosis of neurofibromatosis type 1 (NF1).

3. Presence of symptomatic airway plexiform neurofibromas ; defined by abnormal sleep study or pulmonary function testing.

4. Patients must have measurable (> 1.5 cm in two dimensions or able to assess a minimum of 3 slices) disease by magnetic resonance imaging (MRI).

5. Patients must have a Karnofsky of > 70% or Lansky of > 50% and a life expectancy of > 2 months.

6. Adequate end organ function, defined as the following:

total bilirubin < 1.5 x ULN, SGOT and SGPT < 2.5 x UNL, creatinine < 1.5 x ULN, ANC > 1.5 x 109/L, platelets > 100 x 109/L.

7. Patients must be able to swallow whole pills or crushed pills in a soft food such as pudding or apple sauce; or have other GI access such as a G-tube.

8. Written, voluntary informed consent/assent.

Exclusion Criteria:

1. Patient has received any other investigational agents within 14 days of first day of study drug dosing.

2. Patient is < 5 years free of another primary malignancy except: if the other primary malignancy is not currently clinically significant nor requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ. Existence of any other malignant disease is not allowed.

3. Patient with Grade III/IV cardiac problems as defined by the New York Heart Association Criteria. (i.e., congestive heart failure, myocardial infarction within 6 months of study)

4. Patient has a severe and/or uncontrolled medical disease (i.e., uncontrolled diabetes, chronic renal disease, or active uncontrolled infection).

5. Patient has a known brain metastasis. Non-specific CNS changes on MRI/CT characteristic of NF1 are allowed, but not known CNS malignancies requiring therapeutic intervention.

6. Patient has known chronic liver disease (i.e., chronic active hepatitis, and cirrhosis).

7. Patient has a known diagnosis of human immunodeficiency virus (HIV) infection.

8. Patient received chemotherapy within 4 weeks (6 weeks for nitrosourea or mitomycin-C) prior to study entry.

9. Patient previously received radiotherapy to > 25 % of the bone marrow

10. Patient had a major surgery within 2 weeks prior to study entry.

11. Patient/parent with any significant history of non-compliance to medical regimens or with inability to grant reliable informed consent.

12. Patients who have or anticipate receiving permanent (or semi-permanent) metallic structures attached to their body. (e.g., braces on teeth, body piercings), which their physicians believe will interfere with the MRI.

13. Patient has an unstable airway requiring more urgent intervention or deemed unable to travel due to unstable airway by referring MD.

Related Conditions & MeSH terms

• Neurofibroma
• Neurofibroma, Plexiform
• Neurofibromatoses
• Neurofibromatosis 1

Intervention

Drug:
• Imatinib Mesylate
Imatinib given orally as dose escalation treatment.

Locations

Country	Name	City	State
United States	Riley Hospital for Children - Indiana University	Indianapolis	Indiana

Sponsors (1)

Lead Sponsor	Collaborator
Indiana University

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Quantitative Functional Airway Response	Sleep study or pulmonary function test	12 months
Secondary	Radiologic response of tumor	Volumetric MRI measurements	12 months
Secondary	Quality of Life Assessment	Quality of Life Questionnaire	12 months
Secondary	Cytokine Biomarker	Immunoassay	12 months
Secondary	Inflammatory Cell Biomarker	Flow cytometry	12 months